1. Plasma Product Updates
NAC Meeting, Ottawa
Oct 18-19, 2012
Rick Trifunov
Director, Plasma Products & Services

2. Outline
Recent Customer Letters
SD Plasma
RFP
New Products

3. Recent Changes Customer Letter Product Change 2012-31 Octaplasma
Introduction of new product
HepaGam B
Risk of thrombotic events
Alburex
New Storage Temperature 2-30C
Privigen
Risk of hemolysis
Xyntha
New vial size 3000 IU
Introduction of administration set – Solofuse for 1000, 2000 & 3000
BeneFix 3

4. SD Plasma
SD Plasma
Order Form

5. SD Plasma

6. SD Plasma

7. SD Plasma

8. Request for Proposal
Recognizing the budget pressures of our funders, we are in the process of negotiating new contracts for plasma-derived products for the next 5 years
The need for security of supply and for competitive pricing are key considerations in the RFP
NAC support in this process is critical and valued
We are willing to make supplier changes in order to take advantage of savings, and need physicians and stakeholders to support our decisions regarding brand selection

9. Demand
We need to put plans in place to ensure security of supply and provide the potential for increased supply should demand increase due to new indications
Partnership with suppliers who can give us capacity and priority
Develop plans for continued increase of CBS supplied plasma
New indications could lead us to discussions about how to provide Ig to hospitals going forward—will be a focus of future strategy discussions as we go through next year

10. Utilization
Even without a major change in indications, PPP utilization is increasing year over year
Usage growth is threatening the savings being realized through contract negotiations with suppliers.
CBS is a willing partner in working with physicians and provincial blood coordinating programs to help find measures to effectively control or manage utilization.

11. New Products Being Reviewed in RFP
Vendor
Product(s)
1. Baxter Corporation
FLEXBUMIN
2. Grifols Canada Ltd
Thrombate III
Albutein 25%, 5%, USP1
3. Octapharma Canada Inc
Octagam 10%
Liquid IV IG
Octalbin 25%, 5%
Octanate low volume FVIII/VWD
4. ViroPharma Incorporated
Cinryze (C1 inhibitor) Powder for Solution for Injection2

12. Other New Products Tretten® (rFXIII) RiaSTAP (Fibrinogen concentrate)
Tretten® contains the medicinal ingredient catridecacog which is a coagulation factor. It is indicated for routine prophylaxis for bleeding in patients with congenital Factor XIII A-subunit deficiency.
The product has been licensed in Canada (July 19, 2012), the first country in the world to be licensed.
RiaSTAP (Fibrinogen concentrate)
RiaSTAP is a plasma-derived human fibrinogen concentrate indicated for the treatment of bleeding in patients with congenital hypo-, or afibrinogenaemia with bleeding tendency.
RiaSTAP has been Health Canada licensed, effective from Sept 13, 2012.

13. QUESTIONS?